HeartSciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 08 2022 - 8:30AM
Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS;
HSCSW) (“HeartSciences” or the “Company”), a medical technology
company focused on applying innovative AI-based technology to an
ECG (also known as an EKG) to significantly expand and improve an
ECG’s clinical usefulness by detecting cardiac dysfunction, today
announced that Andrew Simpson, Chairman and Chief Executive Officer
of HeartSciences, will be presenting at the H.C. Wainwright 24th
Annual Global Investment Conference which is being held September
12th - 14th, 2022. The event will include virtual participation as
well as in-person participation at the Lotte New York Palace Hotel
in New York City.
HeartSciences’ presentation will be available
on-demand to registered attendees via the conference platform
beginning Monday, September 12, 2022, at 7:00 AM Eastern Time.
Management will also be participating in one-on-one meetings with
qualified members of the investment community throughout the
conference.
The webcast of the Company’s presentation can
also be
accessed https://journey.ct.events/view/dca5199f-269e-4e10-b942-5c83c1d0e166 and
on the investor relations section of HeartScience's website
at www.heartsciences.com as of 7:00 AM Eastern Time on Monday,
September 12, 2022.
About Heart Test Laboratories, Inc.
Heart Test Laboratories, Inc. (d/b/a HeartSciences) is medical
technology company focused on applying innovative AI-based
technology to an ECG (also known as an EKG) to expand and improve
an ECG’s clinical usefulness by detecting cardiac dysfunction. The
Company’s objective is to make an ECG a far more valuable cardiac
screening tool, particularly in frontline or point-of-care clinical
settings. HeartSciences’ first product candidate for FDA clearance,
the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that
is also designed to provide diagnostic information related to
cardiac dysfunction which has traditionally only been available
through the use of cardiac imaging. The MyoVista also provides
conventional ECG information in the same test. The business model,
which involves the use of the MyoVista device and consumables for
each test, is expected to be “razor-razorblade” as the electrodes
used with the MyoVista are proprietary to HeartSciences, and new
electrodes are required for every test performed. Additional
information about the Company is available at
www.heartsciences.com.
Important Cautions Regarding Forward Looking
Statements
This press release contains certain "forward-looking statements"
within the meaning of federal securities laws. All statements,
other than statements of historical facts, included herein are
"forward-looking statements" including, among other things,
statements about HeartSciences’ beliefs and expectations. The
expectations reflected in these forward-looking statements involve
significant assumptions, risks and uncertainties, and these
expectations may prove to be incorrect. Investors should not place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Potential risks and
uncertainties include, but are not limited to, risks discussed in
HeartSciences’ filings with the U.S. Securities and Exchange
Commission at www.sec.gov. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.
Contact:
Crescendo Communications, LLC Email: HSCS@crescendo-ir.com Tel:
(212) 671-1021
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Sep 2023 to Sep 2024